Capacity Bio

Capacity Bio is a mitochondria-focused biotechnology company developing first-in-class therapeutics that enhance the body's mitophagy process — the cellular mechanism by which dysfunctional mitochondria are identified, removed, and replaced. The company's proprietary platform uses small molecules, peptides, and nanoparticles to activate mitophagy pathways implicated in aging, neurodegeneration, and metabolic disease. Headquartered in Los Angeles and with a Japanese subsidiary in Tokyo, Capacity Bio closed a $35 million financing round in March 2023 co-led by RA Capital Management and Insight Partners, with participation from existing investor Remiges Ventures. Its lead mitophagy agonist program was advancing toward clinical trials in 2024.